Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health Co demonstrated a positive financial performance in 4Q23, reporting revenue of $96.8 million, which exceeded both previous estimates and Street expectations. The company achieved a notable increase in average selling price (ASP) of total systems by approximately 20% quarter-over-quarter, rising to $28.8k, attributed to a higher percentage of direct sales. Additionally, the revenue upside was primarily driven by strong performance in consumables, suggesting a robust demand for the company's innovative aesthetic technologies and products.

Bears say

Beauty Health Co. has demonstrated a concerning trend with its core delivery systems, reporting new placements of 1,210 which reflects a decline of over 30% year-over-year and quarter-over-quarter, significantly below previous estimates. The deceleration in new system placements raises alarms as these systems are critical for driving future consumable sales, which, although exceeding expectations in 4Q23, are vital for achieving profitability targets in 2024. Additionally, management's guidance for 1Q24 shows anticipated sales of $80 million and an adjusted EBITDA loss of $7.5 million, which is notably below prior estimates and suggests a reliance on substantial improvements in the second half of 2024 to meet full-year financial goals.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.